JP2008526927A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526927A5
JP2008526927A5 JP2007550797A JP2007550797A JP2008526927A5 JP 2008526927 A5 JP2008526927 A5 JP 2008526927A5 JP 2007550797 A JP2007550797 A JP 2007550797A JP 2007550797 A JP2007550797 A JP 2007550797A JP 2008526927 A5 JP2008526927 A5 JP 2008526927A5
Authority
JP
Japan
Prior art keywords
oxycodone
pain
formulation
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550797A
Other languages
English (en)
Japanese (ja)
Other versions
JP5049139B2 (ja
JP2008526927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/050252 external-priority patent/WO2006077212A1/en
Publication of JP2008526927A publication Critical patent/JP2008526927A/ja
Publication of JP2008526927A5 publication Critical patent/JP2008526927A5/ja
Application granted granted Critical
Publication of JP5049139B2 publication Critical patent/JP5049139B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007550797A 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用 Expired - Fee Related JP5049139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
US60/645,490 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (3)

Publication Number Publication Date
JP2008526927A JP2008526927A (ja) 2008-07-24
JP2008526927A5 true JP2008526927A5 (https=) 2009-02-05
JP5049139B2 JP5049139B2 (ja) 2012-10-17

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550797A Expired - Fee Related JP5049139B2 (ja) 2005-01-18 2006-01-17 内臓痛を治療するためのオキシコドンの使用

Country Status (31)

Country Link
US (2) US20080200493A1 (https=)
EP (1) EP1838318B1 (https=)
JP (1) JP5049139B2 (https=)
KR (10) KR20230170811A (https=)
CN (1) CN101106996B (https=)
AP (1) AP2249A (https=)
AR (1) AR052880A1 (https=)
AT (2) ATE446092T1 (https=)
AU (1) AU2006207498B2 (https=)
BR (1) BRPI0606247A2 (https=)
CA (1) CA2595043C (https=)
CY (1) CY1109660T1 (https=)
DE (2) DE602006009899D1 (https=)
DK (2) DK1838318T3 (https=)
EA (1) EA013544B1 (https=)
ES (1) ES2333901T3 (https=)
HR (1) HRP20090679T1 (https=)
IL (1) IL184530A (https=)
ME (1) ME01066B (https=)
MX (1) MX2007007207A (https=)
MY (1) MY144471A (https=)
NO (1) NO338968B1 (https=)
NZ (1) NZ555852A (https=)
PL (1) PL1838318T3 (https=)
PT (1) PT1838318E (https=)
RS (1) RS51069B (https=)
SI (1) SI1838318T1 (https=)
TW (1) TWI432196B (https=)
UA (1) UA85471C2 (https=)
WO (1) WO2006077212A1 (https=)
ZA (1) ZA200705231B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069731A1 (en) 2005-11-14 2016-09-21 Labrys Biologics Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
RU2522493C2 (ru) 2008-03-04 2014-07-20 Пфайзер Лимитед Способы лечения хронической боли
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
CN102740884A (zh) 2009-08-28 2012-10-17 瑞纳神经科学公司 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法
PE20141787A1 (es) 2011-05-20 2014-12-07 Alderbio Holdings Llc Composiciones anti-cgrp y uso de las mismas
TWI705825B (zh) 2011-05-20 2020-10-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽(anti-cgrp)或抗降血鈣素基因相關胜肽受器(anti-cgrp-r)抗體或抗體片段治療或預防慢性及急性型腹瀉之用途
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AU2015230933B2 (en) 2014-03-21 2020-08-13 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN109952314A (zh) 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020146527A1 (en) 2019-01-08 2020-07-16 Alder Biopharmaceuticals, Inc. Acute treatment and rapid treatment of headache using anti-cgrp antibodies
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Similar Documents

Publication Publication Date Title
JP2008526927A5 (https=)
JP2022022264A5 (https=)
ES2281851T3 (es) Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
DK2574167T3 (en) LIQUID NOSE SPRAY CONTAINING low-dose naltrexone
TW200528113A (en) Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives
TW200418474A (en) Method of treating post-operative nausea and vomiting
WO2007120485A2 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
HRP20090679T1 (hr) Upotreba oksikodona za liječenje organske boli
JP2008533127A5 (https=)
JP2016507500A5 (https=)
JP2005519936A5 (https=)
JP2009535409A (ja) 即効性ジクロフェナク−オピオイド組成物に基づく急性疼痛医薬
WO2010092436A1 (en) Pharmaceutical combinations of simethicone and otilonium
JP2012516288A (ja) 薬物乱用抑制剤、方法および組成物
US9616066B2 (en) Therapy for constipation
RU2012115450A (ru) Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта
TW200911247A (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease
RU2003135201A (ru) Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами
US10736874B1 (en) Methods for treating pain associated with sickle cell disease
JP5386476B2 (ja) 頭蓋外傷の治療のための4−シクロプロピルメトキシ−n−(3,5−ジクロロ−1−オキシド−4−ピリジン−4−イル)−5−(メトキシ)ピリジン−2−カルボキサミドの使用
CN110279691A (zh) 一种外科术后护理镇痛药物及其用途
US11446311B2 (en) Methods for treating pain associated with sickle cell disease
US8012990B2 (en) Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia
AU2011254554B2 (en) Liquid nasal spray containing low-dose naltrexone
WO2004026291A1 (en) Oral formulations of ibuprofen and tramadol, methods and preparation thereof